Abstract
The review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-low expression are described. The key results of the open multicenter phase III DESTINY-Breast04 (DB-04) trial including safety data are presented. Results on the effectiveness of the drug in patients with markers of hormone resistance first presented in 2023 and the place of trastuzumab deruxtecan in the updated ESMO 2023 algorithm of hormone-positive breast cancer treatment are considered.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.